Nuformix Enters Strategic Cannabinoid Agreement

Cambridge, UK - 9th April 2019

Cambridge, UK, 9 April 2019: Nuformix (LSE: NFX), the pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved small molecule drugs, today announces it has signed an agreement for cannabinoid therapeutics development, licensing and commercialisation comprising up to £51 million of upfront, R&D and milestone payments, plus royalties of 20% of net sales.



Download News

Back to all News